Therapy of Mucormycosis.

Abstract

Despite the recent introduction of mold-active agents (posaconazole and isavuconazole), in addition to amphotericin B products, to our armamentarium against mucormycosis, many uncertainties remain for the management of this uncommon opportunistic infection, as there are no data from prospective randomized clinical trials to guide therapy. In this mini-review, we present the current status of treatment options. In view of the heterogeneity of the disease (different types of affected hosts, sites of infection, and infecting Mucorales), mucormycosis management requires an individualized management plan that takes into account the net state of immunosuppression of the host, including comorbidities, certainty of diagnosis, site of infection, and antifungal pharmacological properties.

• Authors: Nikolaos V Sipsas, Maria N Gamaletsou, Amalia Anastasopoulou, Dimitrios P Kontoyiannis
• Journal: Journal of fungi (Basel, Switzerland) (J Fungi (Basel)) Vol. 4 Issue 3 (Jul 31 2018) ISSN: 2309-608X [Electronic] Switzerland
• PMID: 30065232 (Publication Type: Journal Article, Review)